MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:35Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Corticosteroids]]
			[[Category:Glucocorticoids]]
			[[Category:Inhaled corticosteroids]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #162

2026-05-23T03:56:07Z

parser-claude batch MedTemplate pre-fill, Top 300 #162

New page

{{MedTemplate
| generic = Budesonide
| brand = Pulmicort (inhaled), Rhinocort (intranasal), Entocort EC and Uceris (enteric-coated oral for IBD), Symbicort (with formoterol)
| structure =
| classes = [[:Category:Corticosteroids|Corticosteroid]], [[:Category:Glucocorticoids|Glucocorticoid]], [[:Category:Inhaled_corticosteroids|Inhaled corticosteroid (ICS)]]
| uses = <vote slug="asthma-controller-use">Asthma controller</vote>, <vote slug="copd-use">COPD</vote>, <vote slug="allergic-rhinitis-use">Allergic rhinitis (intranasal)</vote>, <vote slug="croup-use">Croup (nebulized)</vote>, <vote slug="crohn-use">Crohn's disease (oral enteric-coated, ileal/right-colonic disease)</vote>, <vote slug="ulcerative-colitis-use">Ulcerative colitis (Uceris)</vote>
| starting_dose = ICS Pulmicort Flexhaler 180-360 mcg BID; intranasal Rhinocort 64 mcg/spray, 1-2 sprays/nostril daily; Entocort EC 9 mg PO daily for active Crohn's; Symbicort 80/4.5 or 160/4.5 mcg, 2 puffs BID
| preparations = Pulmicort Flexhaler DPI 90, 180 mcg/dose; Pulmicort Respules 0.25, 0.5, 1 mg/2 mL nebulized; Rhinocort intranasal 32 mcg/spray; Entocort EC 3 mg capsules; Uceris 9 mg ER tablets and rectal foam
| fda_max = ICS ~1280 mcg/d; intranasal 256 mcg/d; Entocort 9 mg/d standard
| pill_id =
| routes = Inhaled, intranasal, oral (enteric-coated, rectal foam), nebulized
| onset = Inhaled: bronchial effect 1-2 weeks; oral GI effect 1-2 weeks
| duration = 12-24 hours
| halflife = ~2-3.6 hours (plasma)<ref name="pulmicort-label">FDA Prescribing Information, Pulmicort Flexhaler (budesonide), AstraZeneca, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021949s041lbl.pdf</ref>
| bioavailability = ~6-13% inhaled lung deposition; ~10% oral (Entocort EC; extensive first-pass via CYP3A4 — this is the basis of the favorable hepatic-targeted local-effect profile in IBD)<ref name="pulmicort-label" />
| pregnancy = Long the preferred ICS in pregnancy (Pulmicort) due to the most pregnancy data among the class.{{citation needed}}
| legal = OTC (intranasal Rhinocort Allergy) and [[USLegal:Prescription only|Rx-only]] (other forms) in US
| mechanism = <vote slug="budesonide-mech-claim">Budesonide is a high-potency glucocorticoid receptor agonist designed with high topical receptor affinity and extensive hepatic first-pass to minimize systemic glucocorticoid exposure.</vote> The first-pass property is the basis of enteric-coated oral formulations for IBD: drug is delivered locally to ileum/right colon (Entocort EC) or to colon (Uceris), then largely inactivated on first hepatic pass, sparing systemic steroid exposure. CYP3A4 substrate; strong CYP3A4 inhibitors (ritonavir, ketoconazole) can raise systemic levels enough to produce iatrogenic Cushing's<ref name="pulmicort-label" />.
}}

== References ==
<references />

Budesonide - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #162